Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verve Therapeutics, Inc. - Common Stock (NQ:VERV)

11.13 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verve Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition ↗
Eli Lilly is acquiring Verve Therapeutics to strengthen its cardiovascular pipeline with a gene-editing drug targeting PCSK9-linked conditions. 
Via Benzinga
News headline image
Why Lennar Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Verve Therapeutics Soars 75% After-Hours Following Report Of $1.3B Eli Lilly Takeover Talks ↗
The deal would double Verve’s market value and expand Lilly’s pipeline of early-stage therapies. 
Via Stocktwits
News headline image
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics to Participate in Upcoming Investor Conferences
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results
From Verve Therapeutics
Via GlobeNewswire
News headline image
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst ↗
CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025. 
Via Benzinga
News headline image
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
News headline image
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street ↗
Via The Motley Fool
News headline image
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Why Verve Therapeutics Zoomed 40% Higher This Week ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Unusual volume stocks are being observed in Tuesday's session. ↗
Let's have a look at the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Verve Therapeutics Is Skyrocketing Today ↗
Via The Motley Fool
News headline image
The market is filled with gapping stocks in Tuesday's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
News headline image
Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Assessing Verve Therapeutics: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose ↗
Verve shares Phase 1b results of VERVE-102, showing dose-dependent LDL-C reductions and strong safety in patients with HeFH or premature CAD. 
Via Benzinga
News headline image
These stocks are moving in today's pre-market session ↗
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
From Verve Therapeutics
Via GlobeNewswire
News headline image
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors 
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones
From Verve Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.